Clinical Trials Sponsored by I-Mab Biopharma Co. Ltd.

Total 252 results

I-Mab Biopharma Co. Ltd.

Recruiting

A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

Coronavirus Disease 2019 COVID-19

United States
I-Mab Biopharma Co. Ltd.

No longer available

Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001

Solid Tumor Metastatic Cancer Advanced Cancer
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects

Healthy Adult Subjects

United States
I-Mab Biopharma Co. Ltd.

Recruiting

Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors

Gastric Cancer | Solid Tumor | Metastatic Cancer | Advanced Cancer | Esophageal Adenocarcinoma | Gastroesophageal Junction Carcinoma

United States, China
I-Mab Biopharma Co. Ltd.

Recruiting

A Study of TJ003234 in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

China
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors

Solid Tumor | Metastatic Cancer | Advanced Cancer

United States
I-Mab Biopharma US Limited

No longer available

Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer

Cancer

United States
I-Mab Biopharma US Limited

Completed

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Head and Neck Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Gastrointestinal Cancer | Ovarian Carcinoma

United States
AbbVie
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Lymphoma | Solid Tumor

United States, China
I-Mab Biopharma HongKong Limited

Completed

Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis

Active Ulcerative Colitis

China, Taiwan, Korea, Republic of
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

Assessment of Anti-RANKL Antibody in Post-menopausal Women

Osteoporosis

China
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
Jiangsu T-Mab Biopharma Co.,Ltd

Completed

Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects

Chemotherapy-induced Neutropenia

China
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer

Chemotherapy-induced Neutropenia

China
Jiangsu T-Mab Biopharma Co.,Ltd

Completed

Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors

Chemotherapy-induced Neutropenia | Metastatic Tumors

China
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases

Breast Cancer
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases

Breast Cancer

China
WestVac Biopharma Co., Ltd.
WestVac Biopharma (Guangzhou) Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

COVID-19

China
JKT Biopharma Co., Ltd.

Not yet recruiting

SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)

COVID-19

China
TJ Biopharma Co., Ltd.

Recruiting

Study of Felzartamab in Healthy Adult Subjects

Healthy

China
JKT Biopharma Co., Ltd.

Recruiting

The Safety, Tolerability, Pharmacokinetics and Food Effects of SHEN211 Tablet in Healthy Subjects

Phase 1

China
WestVac Biopharma Co., Ltd.

Not yet recruiting

A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination

COVID-19
TJ Biopharma Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes(MDS)

China
Boryung Biopharma Co., Ltd.

Not yet recruiting

To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs

Hepatitis A | Hep A

Korea, Republic of, Thailand
WestVac Biopharma Co., Ltd.

Not yet recruiting

A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)

COVID-19 | SARS-CoV-2 Pneumonia

China
WestVac Biopharma Co., Ltd.

Recruiting

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

Philippines
Genor Biopharma Co., Ltd.

Recruiting

A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

CLL | B Cell NHL

Australia
Haihe Biopharma Co., Ltd.

Recruiting

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

C-Met Exon 14 Mutation

China, Japan, United States
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
TJ Biopharma Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

Newly Diagnosed Glioblastoma

China, Hong Kong
TJ Biopharma Co., Ltd.

Active, not recruiting

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Advanced Solid Tumor

China
TJ Biopharma Co., Ltd.

Terminated

A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

Advanced Solid Tumor

China
Haihe Biopharma Co., Ltd.

Terminated

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Breast Cancer | Ovarian Cancer | Solid Tumor | Prostate Cancer | Endometrial Cancer

United States, Australia, China
HanAll BioPharma Co., Ltd.

Completed

A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes (VELOS-1)

Dry Eye

United States
Genor Biopharma Co., Ltd.

Completed

A Study of [14C]GB491 in Male Healthy Subjects

Breast Cancer | Nonsmall Cell Lung Cancer

China
Genor Biopharma Co., Ltd.

Completed

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

Breast Cancer

China
Newsoara Biopharma Co., Ltd.

Unknown

Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers

Healthy

China
Boryung Biopharma Co., Ltd.

Unknown

To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years (Aladdin)

Pertussis | Tetanus | Diphtheria | Poliomyelitis

Korea, Republic of
Haihe Biopharma Co., Ltd.

Unknown

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Negative T790M Mutation and Met Amplification

China
Haihe Biopharma Co., Ltd.

Unknown

Study to Evaluate the Safety and Anti-tumor Activity of SCC244

Advanced Solid Tumor

China
Haihe Biopharma Co., Ltd.

Unknown

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Extensive-stage Small Cell Lung Cancer

China
Genor Biopharma Co., Ltd.

Unknown

Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects

Rheumatoid Arthritis

China
Genor Biopharma Co., Ltd.

Unknown

Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection

Rheumatoid Arthritis

China
Genor Biopharma Co., Ltd.

Unknown

Clinical Trial in Chinese Healthy Volunteers of GB222

Non-small Cell Lung Cancer

China
HanAll BioPharma Co., Ltd.

Completed

Phase 1 Study for Safety and Tolerability of HL036

Dry Eye

Korea, Republic of
HanAll BioPharma Co., Ltd.

Completed

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

Prostate Cancer

Korea, Republic of
HanAll BioPharma Co., Ltd.

Completed

Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone

Hypertension

Korea, Republic of
Newsoara Biopharma Co., Ltd.

Not yet recruiting

HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

NSCLC Stage IV

3

Subscribe